British genomics interpretation software vendor Congenica inked a deal with a Portuguese hospital to analyze whole-exome sequencing data for the In2Genome project.
The companies will combine OpGen's Acuitas Rapid Test for Pathogen ID and Thermo Fisher's new mid-throughput real-time PCR system.
WeGene will use DNA Genotek's saliva DNA collection kits for its genetic testing and personalized healthcare services.
The institute has selected the firm's RNA-seq library preparation kits for use in gene expression profiling in single-cell analysis of brain cells.
Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.
The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.
Under the terms of the agreement, Natera will develop in vitro diagnostic products for oncology and pay Illumina milestone payments and royalties.
Seattle-based chemical manufacturer Arzeda will buy megabase quantities of synthetic DNA from Gen9 for use in developing new advanced molecules.
The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.
Norgen Biotek's sample prep products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.